Oncolytic virotherapy

Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy
Hena Khalique, Richard Baugh, Arthur Dyer, Eleanor M. Scott, Sally Frost, Sarah Larkin, Janet Lei-Rossmann, Leonard W. Seymour

Journal for ImmunoTherapy of Cancer Mar 2021, 9 (4) e001292; DOI: 10.1136/jitc-2020-001292
Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy
Dong Ho Shin, Teresa Nguyen, Bulent Ozpolat, Frederick Lang, Marta Alonso, Candelaria Gomez-Manzano, Juan Fueyo

Journal for ImmunoTherapy of Cancer Apr 2021, 9 (4) e002086; DOI: 10.1136/jitc-2020-002086
Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
Josep Malvehy, Igor Samoylenko, Dirk Schadendorf, Ralf Gutzmer, Jean-Jacques Grob, Joseph J Sacco, Kevin S Gorski, Abraham Anderson, Cheryl A Pickett, Kate Liu, Helen Gogas

Journal for ImmunoTherapy of Cancer Mar 2021, 9 (3) e001621; DOI: 10.1136/jitc-2020-001621
Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma
Alvaro Morales-Molina, Stefano Gambera, Angela Leo, Javier García-Castro

Journal for ImmunoTherapy of Cancer Mar 2021, 9 (3) e001703; DOI: 10.1136/jitc-2020-001703
Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis
Simon Gebremeskel, Adam Nelson, Brynn Walker, Tora Oliphant, Lynnea Lobert, Douglas Mahoney, Brent Johnston

Journal for ImmunoTherapy of Cancer Mar 2021, 9 (3) e002096; DOI: 10.1136/jitc-2020-002096
In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
Adrianne L Jenner, Tyler Cassidy, Katia Belaid, Marie-Claude Bourgeois-Daigneault, Morgan Craig

Journal for ImmunoTherapy of Cancer Feb 2021, 9 (2) e001387; DOI: 10.1136/jitc-2020-001387
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Julia Maria Ressler, Matthias Karasek, Lukas Koch, Rita Silmbrod, Joanna Mangana, Sofiya Latifyan, Veronica Aedo-Lopez, Helmut Kehrer, Felix Weihsengruber, Peter Koelblinger, Christian Posch, Julian Kofler, Olivier Michielin, Erika Richtig, Christine Hafner, Christoph Hoeller

Journal for ImmunoTherapy of Cancer Feb 2021, 9 (2) e001701; DOI: 10.1136/jitc-2020-001701
Mesenchymal stem cells and oncolytic viruses: joining forces against cancer
Rafael Moreno

Journal for ImmunoTherapy of Cancer Feb 2021, 9 (2) e001684; DOI: 10.1136/jitc-2020-001684
IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
Tianyue Chen, Xiangqing Ding, Qibin Liao, Nan Gao, Ye Chen, Chen Zhao, Xiaoyan Zhang, Jianqing Xu

Journal for ImmunoTherapy of Cancer Jan 2021, 9 (1) e001647; DOI: 10.1136/jitc-2020-001647
Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer
Yu Seong Lee, Won Suk Lee, Chang Woo Kim, Seung Joon Lee, Hannah Yang, So Jung Kong, John Ning, Kyung-Mee Yang, Beodeul Kang, Woo Ram Kim, Hong Jae Chon, Chan Kim

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (2) e000857; DOI: 10.1136/jitc-2020-000857

Main menu

Oncolytic virotherapy

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Oncolytic virotherapy

Pages